Elutia

Update in progress

ELUT (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryMedical Devices

Elutia Inc. develops drug-eluting biomatrix products for surgical reconstruction, operating in Women’s Health and Cardiovascular. Its lead programs, NXT-41 and NXT-41x, are biologic scaffolds with local antibiotic delivery. SimpliDerm is a human acellular dermal matrix for soft-tissue reconstruction. ProxiCor and Tyke are cardiac patch/matrix products for repairs and pericardial closure; VasCure supports peripheral vasculature. Sold to hospitals via independent agents. Formerly Aziyo Biologics; renamed 2023. Based in Gaithersburg, MD.

Company score

Sentiment: 0.32; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.19; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.08; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.19; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive